Why Scholar Rock Stock Raced 6% Higher Today
Key Points
An analyst launched coverage of the clinical-stage biotech.
She singled out one of its pipeline candidates as having oversized potential.
- 10 stocks we like better than Scholar Rock ›
An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (NASDAQ: SRRK) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on a trading day when the benchmark S&P 500 (SNPINDEX: ^GSPC) sagged by 0.3%.
A rock of a stock
Well before market open, Tazeen Ahmad of Bank of America Securities launched her tracking of Scholar Rock.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
The reason the market reacted so strongly and positively to this is because Ahmad flagged it as a buy, at a price target of $53 per share. That's nearly 30% higher than the company's most recent closing price, even after Thursday's pop.
The analyst is particularly taken by Scholar Rock's investigational spinal muscular atrophy (SMA) drug apitegromab, according to reports. So far in its development, the medication appears to be significantly more efficacious than current treatments on the market.
The leading pipeline drug
Scholar Rock's strategy is to focus on developing drugs for relatively uncommon afflictions, such as SMA, that don't yet have effective and approved therapies.
Apitegromab is the company's most advanced pipeline drug. It has been submitted under a biologics license application (BLA) for U.S. Food and Drug Administration (FDA) approval. However, last month the regulator issued a complete response letter (CRL; or notification that an application isn't approved in its current form). Scholar Rock is working to rectify the issues detailed in the CRL.
Should you invest $1,000 in Scholar Rock right now?
Before you buy stock in Scholar Rock, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Scholar Rock wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $654,835!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,159,218!*
Now, it’s worth noting Stock Advisor’s total average return is 1,081% — a market-crushing outperformance compared to 192% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 7, 2025
Bank of America is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
